Working… Menu

Evaluation of the TriActiv ProGuard System During Carotid Artery Stenting

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00395785
Recruitment Status : Terminated (Sponsor elected to not pursue this indication for the study device.)
First Posted : November 3, 2006
Last Update Posted : July 25, 2007
Information provided by:
Kensey Nash Corporation

Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of the TriActiv® ProGuard™ System when used during a stent placement in a blockage within the carotid artery in patients considered to be at high risk for complications from surgical endarterectomy.

Condition or disease Intervention/treatment Phase
Carotid Stenosis Device: Carotid Stent Implantation Device: Embolic Protection Phase 2 Phase 3

Detailed Description:
Patients with certain anatomic or medical conditions have a greater risk of serious complications following carotid endarterectomy (a surgical procedure that removes blockages in the carotid artery). Recently, these patients have been treated effectively with the implantation of a carotid stent (a metallic mesh tube). When implanting the carotid stent, physicians use devices called embolic protection devices to prevent particles from the blockage from flowing up to the brain. The TriActiv® ProGuard™ System is an embolic protection device that uses a small balloon to temporarily stop blood flow within the diseased carotid artery while the stent is implanted. Then, the TriActiv® ProGuard™ System removes any particles that may have been released from the blockage during stent implantation before blood flow is restored. This study will evaluate the safety and efficacy of the TriActiv® ProGuard™ System during carotid stent placement in patients who are considered to be at a high risk for complications from surgical endarterectomy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Protection During Carotid Stenting in High Risk Patients With the TriActiv ProGuard System
Study Start Date : November 2006
Actual Study Completion Date : June 2007

Primary Outcome Measures :
  1. A composite of major adverse events including any death, any stroke and/or myocardial infarction through thirty days post-procedure.

Secondary Outcome Measures :
  1. Rate of subject intolerance to prolonged carotid artery occlusion;
  2. Rate of access site complications requiring treatment with blood transfusion or surgical repair.
  3. Rate of successful use of the study device success
  4. Rate of successful lesion treatment
  5. Rate of procedure success

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Greater than 18 year of age
  • Patient gives informed consent
  • Less than 30mm stenosis in the common and/or internal carotid artery: at least a 50% stenosis if symptomatic or at least an 80% stenosis if asymptomatic
  • At least one medical or anatomic condition which makes the patient a high surgical risk.

Exclusion Criteria:

  • Stroke within 14 days
  • Major stroke with significant residual effects
  • Myocardial infarction within 72 hours
  • Extensive atherosclerotic disease in the aortic arch or proximal common carotid artery
  • Severe carotid artery tortuosity
  • Total occlusion
  • Presence of thrombus or heavy calcification in the carotid artery
  • Pre-existing carotid artery dissection
  • Any planned interventional or surgical procedures within 30 days
  • Atrial fibrillation
  • Creatinine > 2 mg/dL
  • Current participation in another investigational drug or device study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00395785

  Show 34 Study Locations
Sponsors and Collaborators
Kensey Nash Corporation
Layout table for investigator information
Principal Investigator: Gary S Roubin, MD Lenox Hill Hospital, New York, NY
Principal Investigator: Rajesh Dave, MD Pinnacle Health Hospital, Harrisburg, PA

Layout table for additonal information Identifier: NCT00395785     History of Changes
Other Study ID Numbers: PROGUARD
First Posted: November 3, 2006    Key Record Dates
Last Update Posted: July 25, 2007
Last Verified: July 2007
Keywords provided by Kensey Nash Corporation:
Carotid stenosis
Intracranial Embolism
Carotid artery
Carotid stent
Embolic protection
TriActiv ProGuard System
Carotid angioplasty
Additional relevant MeSH terms:
Layout table for MeSH terms
Carotid Stenosis
Carotid Artery Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases